Antibiotice Iași: Balanced Development, Strategic Investments, and International Expansion

On May 14, 2025, Antibiotice SA (stock symbol: ATB) published its economic and financial results for the first quarter of the year. In the context of global instability and particularly national events affecting the economy and financial policies, Antibiotice continues to strengthen its profitability rate and market position, both domestically and internationally. This confirms the sustainability of its balanced and long-term growth strategy.

Key financial results for Q1 2025:

• Total revenue: 180.03 million RON;
• Gross profit: 35.34 million RON, corresponding to a profitability rate of 21.9%, up by 3% compared to Q1 2024;
• Business return (gross profit + claw-back tax): 27.8%;
• Market leader in terms of value with a 13.6% hospital market share for generic OTC and Rx products (according to Cegedim, March 2025);
• Average share price: 2.3745 RON/share.

Strengthened position on the Romanian pharmaceutical market

Antibiotice ranks 4th out of 361 active companies in Romania based on consumption (measured in number of units), holding a 4.5% market share in the generics segment (both OTC and prescription). The company is the volume leader for several pharmaceutical forms: ointments (19.7%), suppositories and ovules (33.4%), and injectable powders (60.2%). It also ranks 3rd in the capsules segment (5.6%).

Sustained growth and portfolio diversification

During the first quarter, three new products were launched: a prescription medicine for hormone replacement therapy and two dietary supplements aimed at supporting women’s health during menopause and men’s health. These products target both domestic and international markets.

International expansion aligned with strategic objectives

International sales revenues totaled 75.9 million RON (15 million EUR). Growth was primarily driven by the expansion of finished product exports in Europe, in line with the company’s business plan, offering strong development prospects.

Antibiotice continued commercial negotiations in Germany, Italy, Spain, Poland, Hungary, the Czech Republic, and Slovakia for launching authorized products and selecting portfolios for future registration.

In Germany, one of the largest pharmaceutical markets in Europe, a distribution agreement was signed for two injectable products, with the first deliveries scheduled for Q4 2025. Additionally, advanced discussions began regarding the registration of a topical product portfolio.

In Italy, new tenders were won for an injectable product from the company’s portfolio, expected to secure an estimated 40% market share for that molecule.

In Vietnam, four new cardiovascular products were launched through two new local partners.

Antibiotice maintained its growth trend in the global API market, with deliveries to over 55 countries. Between January and March 2025, progress was made in strategic projects across Europe, North America, and Latin America, reinforcing strong development prospects in these regions.

Operational efficiency and financial stability

During the reporting period, the company operated in line with its business strategy “The Future Together,” successfully maintaining its profitability rate and reaching a net turnover of 161.12 million RON.

Key financial stability indicators for Q1 2025:

• • Current liquidity (current assets/short-term bank liabilities): 9.47, significantly above the recommended threshold of 1.2;
  • Total bank debt (sum of operational and investment loan balances):
    • Total bank debt/EBITDA: 1.34, below the recommended maximum of 3.5;
    • Total bank debt/equity: 0.22, below the recommended maximum of 1.

Strategic investments in development and modernization

In Q1 2025, Antibiotice Iași made investments totaling 11.25 million RON, aligned with the annual investment plan, aimed at consolidating and modernizing its capabilities.

The majority of the investments—8.4 million RON—were directed towards projects under the InvestEU – Strategic Development program, targeting:

• • • Product portfolio development through R&D investments;
    • Expansion of industrial capacities, including ongoing work on a new facility for the manufacturing, packaging, and storage of sterile products.

The finished product warehouse, completed at the end of last year, was officially authorized by the National Agency for Medicines and Medical Devices of Romania (ANMDMR) during the reporting period.

At the same time, the company continued its digital transformation by implementing an ERP system, modernizing IT networks, and strengthening cybersecurity.

Investments to consolidate the business, amounting to 3.2 million RON, were directed toward utility infrastructure modernization, compliance with environmental requirements, equipping quality control laboratories, and upgrading manufacturing processes.

Investments in human resource development through EU funds

During the reporting period, Antibiotice Iași secured 1.5 million euros in European funding for human resource development through two projects carried out via its knowledge management platform, Academia a+:

• • • “Education in Action: Improving Accessibility and Relevance of Vocational and Technical Education through Internships at Antibiotice S.A.”
    • “AntibioticeSkills: Enhancing Students’ Skills and Preparing Them for the Labor Market”

These projects support internship programs for over 500 high school and university students, contributing to the development of professional, entrepreneurial, and digital skills. The initiatives are supported by the European Social Fund Plus and will continue through 2027.

***

Those interested in further information may consult the Q1 2025 Administrators’ Report available on the websites of the Bucharest Stock Exchange (www.bvb.ro), the Financial Supervisory Authority (www.asfromania.ro) or Antibiotice S.A. (www.antibiotice.ro), under the section “Investors > Financial Information > Financial Reports”.